FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1(c). Se	ee Instruction 1	0.																		
Name and Address of Reporting Person* Ma Songjiang						2. Issuer Name and Ticker or Trading Symbol GYRE THERAPEUTICS, INC. [GYRE]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
<u>Ma Songjiang</u>														1	Director			10% O		
														1	Office	er (give title		Other (s	specify	
(Last) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year) 12/30/2024									Delov	,	siden	,		
C/O GYRE THERAPEUTICS, INC.						12/30/2027										1108	siucii	ι		
12770 HIGH BLUFF DRIVE, SUITE 150														O leditidad on leid/Orace Filips (Obsala 1 1 1 1						
(Chroat)						4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line)						
(Street) SAN DIEGO CA 92130														1	<u></u>					
SAN DIEGO CA 92130															Form filed by More than One Reporting Person					
(City)	(State) (Zip)																			
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
1. Title of Security (Instr. 3) 2. Transact Date						Execution			3. 4. Securitie Transaction Disposed 0					Owned Following		6. Ownership Form: Direct		7. Nature of Indirect		
(Month/Day					y/Year)	//Year) if any (Month/Day/Year)			Code (Instr. 5) 8)									Beneficial Ownership		
									Code V		A	(A)	or Pric	-		eported ransaction(s)			(Instr. 4)	
									Code	Ľ	Amount	(D)	Pric	е		3 and 4)				
Common Stock 12/30/2						2024					2,000		(_{@1/}	5(2)	2.0	24.467		, l	Ву	
Common Stock 12/30/2					.024				S ⁽¹⁾		2,000		Ψ12	\$12.5(2)		2,924,467		1	Spouse	
Common Stock 12/31/2					0024				S (1)		2,000	D	\$12	2.3(3)	2,922,467		I		By	
Common Stock 12/31/2					.024				3		2,000		Ψ12	2.3	2,722,407			1	Spouse	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
					•	alis, v		_				1		÷						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	emed ion Date, /Day/Year)		Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Exercion Da /Day/Y		7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		Der Sec (Ins	Price of rivative curity str. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amount or Number of Shares							

Explanation of Responses:

- 1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.
- 2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from \$12.07 to \$12.75. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- 3. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from \$12.01 to \$12.76. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

/s/ Songjiang Ma

01/02/2025

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.